Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Veliparib, paklitaxel och karboplatin vid behandling av patienter med solida tumörer som är metastaserande eller inte kan avlägsnas genom kirurgi och lever- eller njurfunktion

17 november 2026 uppdaterad av: National Cancer Institute (NCI)

En tidig fas 1-studie av ABT-888 i kombination med karboplatin och paklitaxel hos patienter med nedsatt lever- eller njurfunktion och solida tumörer

This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Intervention / Behandling

Detaljerad beskrivning

PRIMARY OBJECTIVES:

I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.

II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.

III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.

SECONDARY OBJECTIVES:

I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.

III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.

OUTLINE: This is a dose-escalation study of veliparib.

Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

After completion of study treatment, patients are followed up for 4 weeks.

Studietyp

Interventionell

Inskrivning (Faktisk)

94

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Duarte, California, Förenta staterna, 91010
        • City of Hope Comprehensive Cancer Center
      • Sacramento, California, Förenta staterna, 95817
        • University of California Davis Comprehensive Cancer Center
      • South Pasadena, California, Förenta staterna, 91030
        • City of Hope South Pasadena
    • Florida
      • Tampa, Florida, Förenta staterna, 33612
        • Moffitt Cancer Center
    • Georgia
      • Atlanta, Georgia, Förenta staterna, 30322
        • Emory University Hospital/Winship Cancer Institute
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21287
        • Johns Hopkins University/Sidney Kimmel Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, Förenta staterna, 48201
        • Wayne State University/Karmanos Cancer Institute
    • New Jersey
      • New Brunswick, New Jersey, Förenta staterna, 08903
        • Rutgers Cancer Institute of New Jersey
    • New York
      • New York, New York, Förenta staterna, 10065
        • Memorial Sloan Kettering Cancer Center
      • The Bronx, New York, Förenta staterna, 10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx, New York, Förenta staterna, 10461
        • Montefiore Medical Center-Weiler Hospital
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • Case Western Reserve University
    • Pennsylvania
      • Hershey, Pennsylvania, Förenta staterna, 17033-0850
        • Penn State Milton S Hershey Medical Center
      • Pittsburgh, Pennsylvania, Förenta staterna, 15232
        • UPMC Hillman Cancer Center
    • Texas
      • Houston, Texas, Förenta staterna, 77030
        • UT MD Anderson Cancer Center
    • Wisconsin
      • Madison, Wisconsin, Förenta staterna, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
  • Life expectancy of greater than 12 weeks
  • Absolute neutrophil count >= 1,500/mcL
  • Platelets >= 100,000/mcL
  • Hemoglobin >= 8.0 g/dL
  • Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
  • Total bilirubin =< 5 x upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
  • For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
  • Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
  • Patients may not be receiving any other investigational agents
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
  • Peripheral neuropathy of severity greater than grade 1
  • Inability to take oral medications on a continuous basis
  • Evidence of bleeding diathesis
  • Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
  • Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
  • Patients with both hepatic and renal dysfunction will also be excluded
  • Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
  • Active seizure or history of seizure disorder

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: N/A
  • Interventionsmodell: Enskild gruppuppgift
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Treatment (veliparib, paclitaxel, carboplatin)

Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.

NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).

Given IV

Andra namn:
  • Blastocarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatina
  • Paraplatin
  • Paraplatin AQ
  • Platinwas
  • Ribocarbo
  • JM8

Given IV

Andra namn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Correlative studies

Given PO

Andra namn:
  • ABT-888
  • PARP-1-hämmare ABT-888
  • ABT 888
  • ABT888

Correlative studies

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
MTD för veliparib i kombination med karboplatin och paklitaxel, bestämt enligt incidensen av DLT som graderats med hjälp av National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version (v) 4.0
Tidsram: 21 dagar
21 dagar
PK parameters of veliparib
Tidsram: Day -6 and 3 of course 1 after veliparib dosing

Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test.

Day -6 and 3 of course 1 after veliparib dosing

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence of toxicities as assessed by NCI CTCAE v4.0
Tidsram: Up to 4 weeks after completion of study treatment

The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data.

Up to 4 weeks after completion of study treatment
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Tidsram: Up to 4 weeks after completion of study treatment

Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates.

Up to 4 weeks after completion of study treatment
Incidence of stable disease as assessed by RECIST version 1.1
Tidsram: Up to 4 weeks after completion of study treatment

Incidence of stable disease will be tabulated by disease diagnosis and by dose level.

Up to 4 weeks after completion of study treatment
Time to progression
Tidsram: Up to 4 weeks after completion of study treatment

Displayed for all patients and for patients who have responded; no formal statistical analysis is planned.

Up to 4 weeks after completion of study treatment

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Change in PAR levels
Tidsram: Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks
Change in gamma-H2AX levels
Tidsram: Baseline to up to 4 weeks

Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test.

Baseline to up to 4 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Samarbetspartners

Utredare

  • Huvudutredare: Hussein A Tawbi, University of Pittsburgh Cancer Institute (UPCI)

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

20 juni 2011

Primärt slutförande (Faktisk)

10 november 2017

Avslutad studie (Beräknad)

3 mars 2027

Studieregistreringsdatum

Först inskickad

2 juni 2011

Först inskickad som uppfyllde QC-kriterierna

2 juni 2011

Första postat (Beräknad)

3 juni 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 november 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • NCI-2011-02500
  • U01CA070095 (U.S.S. NIH-anslag/kontrakt)
  • UM1CA186691 (U.S.S. NIH-anslag/kontrakt)
  • UM1CA186716 (U.S.S. NIH-anslag/kontrakt)
  • U01CA099168 (U.S.S. NIH-anslag/kontrakt)
  • U01CA062502 (U.S.S. NIH-anslag/kontrakt)
  • U01CA062505 (U.S.S. NIH-anslag/kontrakt)
  • U01CA062490 (U.S.S. NIH-anslag/kontrakt)
  • U01CA069856 (U.S.S. NIH-anslag/kontrakt)
  • UM1CA186690 (U.S.S. NIH-anslag/kontrakt)
  • UM1CA186717 (U.S.S. NIH-anslag/kontrakt)
  • UM1CA186709 (U.S.S. NIH-anslag/kontrakt)
  • N01CM00100 (U.S.S. NIH-anslag/kontrakt)
  • P30CA047904 (U.S.S. NIH-anslag/kontrakt)
  • NCI-2011-02500 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
  • CDR0000700997
  • UPCI 10-115
  • UPCI-10-115
  • 8808 (Annan identifierare: CTEP)
  • 8808 (Annan identifierare: UPMC Hillman Cancer Center)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .